Managers

Bessemer launches $1.85 bln fund

Bessemer Venture Partners has launched an $1.85 billion fund. BVP X will focus on investing in early-stage tech companies.

Sitka Biopharma nets $1.9 mln

Vancouver, British Columbia-based Sitka Biopharma, a preclinical biotechnology company, has raised $1.9 million in funding. The investors were Quark Venture Inc. and GF Securities. The capital will be used to complete Sitka's clinical trials for a drug that treats bladder cancer.

Venture capital distributions rose 14 percent last year

Milestone Pharmaceuticals amasses $80 mln

Montreal-based Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing interventions for tachycardias, has closed $80 million in financing. RTW Investments LP led the round with participation from other investors that included Venrock Healthcare Capital Partners, Boxer Capital of Tavistock Group, Novo Holdings A/S, Forbion, funds managed by Tekla Capital Management LLC, Domain Associates, BDC Capital, Pappas Capital, GO Capital and Fonds de solidarité FTQ.

89Bio nabs $60 mln Series A

San Francisco and Israel-based 89Bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis and other liver and metabolic disorders, has raised $60 million in Series A financing. OrbiMed Israel, OrbiMed US and Longitude Capital led the round with participation from RA Capital Management and Pontifax.

Fund Performance: PSERS venture portfolio, vintages 2003 to 2007

Venture investing slows in Europe, but fundraising strong in Q3

VC funds celebrate most successful haul in six years

Camber Creek’s Berman on his new fund and disrupting the real estate market

Thrive Capital raises $1 bln sixth venture fund for multi-stage investing